PF 04217903 mesylate

Cat. No. 4239

PF 04217903 mesylate C19H16N8O.CH3SO3H [956906-93-7]

Price and Availability

For PF 04217903 mesylate pricing & availability please select your country from the drop down menu:
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 4-[1-(6-Quinolinylmethyl)-1H-1,2,3-triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazole-1-ethanol mesylate

Biological Activity

Highly selective, high affinity c-Met inhibitor (Ki = 6-7 nM against wild type c-Met). Displays >1000-fold selectivity for c-Met over a panel of 208 kinases.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

Soluble to 100 mM in DMSO
>98 %
Store at +4°C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet


Eder et al (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin.Cancer Res. 15 2207. PMID: 19318488.

Timofeevski et al (2009) Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 48 5339. PMID: 19459657.

Underiner et al (2010) Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med.Chem. 10 7. PMID: 20015007.

Cui et al (2012) Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. J.Med.Chem. 55 8091. PMID: 22924734.

If you know of a relevant citation for this product please let us know.

Keywords: PF 04217903 mesylate, supplier, pfizer, PF04217903, c-met, met, mesenchymal, epithelial, transition, factor, hgfr, receptors, tyrosine, kinase, rtk, inhibitors, anticancer, selective

Quick Order

Find multiple products by catalog number

divider line

Kinases Product Listing

Kinases Product Listing

Highlights over 400 products for kinase research. Request a copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

New Product Guide


Highlights 130 new products added in the first half of 2015. View PDF today.

divider line

New Products in this Area

PF 06463922

High affinity and selective ALK and ROS1 inhibitor


Insulin degrading enzyme (IDE) inhibitor


Potent c-MET/ALK inhibitor

AC 710

Potent and selective PDGFR family inhibitor

SPP 86

Potent RET inhibitor

SGX 523

Selective and potent c-MET kinase inhibitor

Sign-up for new product e-alerts
divider line

Bio-Techne Events


Neuroscience 2015

October 17-21, 2015

Chicago, IL